The STUDIA UNIVERSITATIS BABE┼×-BOLYAI issue article summary

The summary of the selected article appears at the bottom of the page. In order to get back to the contents of the issue this article belongs to you have to access the link from the title. In order to see all the articles of the archive which have as author/co-author one of the authors mentioned below, you have to access the link from the author's name.

 
       
         
    STUDIA CHEMIA - Issue no. 2 / 2020  
         
  Article:   KINETICS OF GLICLAZIDE AFTER SINGLE DOSE ORAL ADMINISTRATION OF GLICLAZIDE 60 MG MODIFIED RELEASE TABLET.

Authors:  DIANA IOANA POP, ADRIANA MARCOVICI, MONICA OROIAN, ANA-MARIA GHELDIU, LAURIAN VLASE.
 
       
         
  Abstract:  
DOI: 10.24193/subbchem.2020.2.15

Published Online: 2020-06-30
Published Print: 2020-06-30
pp. 187-196
VIEW PDF: FULL PDF

ABSTRACT: The current study aimed to establish and describe the basic pharmacokinetics of a single dose of gliclazide 60 mg modified release formulation manufactured by Ranbaxy Laboratories Limited, now Sun Pharmaceutical Industries Limited, India. Ten mathematical models were created for analyzing the experimental data resulted from two bioequivalence studies conducted at Clinical Pharmacology and Pharmacokinetics Department of Terapia S.A. Model discrimination was done using the Akaike index value and it was observed that model number 10 (M10) is the model that best describes the gliclazide disposition. This model has two compartments (peripheral and central), mixed order absorption process (1st and zero order kinetics) with a lag time of around 3 hrs and 1st order kinetics of elimination. Applying this model in Phoenix software version 6.3 (Pharsight Corp., Mountain view, CA, USA) the main pharmacokinetic parameters of gliclazide were also computed.

Key words: gliclazide, compartmental pharmacokinetic analysis, bioequivalence clinical trials, best model
 
         
     
         
         
      Back to previous page